What does “ascciminib synthesis” mean in the US patent context?
Asciminib is the active pharmaceutical ingredient in Scemblix (and related products). When people search “US patent asciminib synthesis,” they usually want one of two things: (1) which US patents disclose how to make asciminib (synthetic routes, intermediates, reagents), or (2) whether those patents are still active and block generic or alternative manufacturing.
Which US patents describe methods to synthesize asciminib?
A targeted way to find US patent documents that include asciminib synthesis is to search patent databases by the compound name (asciminib) and key chemical terms (e.g., “preparation,” “process,” “intermediate,” “example,” “compound of formula,” “Step,” or specific intermediate names used in the disclosures). Patent claims may cover the overall manufacturing method, specific intermediates, or purification steps, so the “synthesis” content is often split across multiple documents.
If you want, tell me whether you’re looking for:
- the main published synthetic route (examples),
- a specific intermediate,
- a process/purification improvement, or
- patent numbers you already found (then I can help interpret what each one covers).
How can I check whether asciminib synthesis patents still matter for manufacturing?
For “synthesis” patents, the practical question is whether a given US patent is still in force (or has expired) and whether it has exclusivity protections tied to the drug product. DrugPatentWatch.com is one place to track patents and exclusivity around a brand like Scemblix and then link that back to the underlying US patent documents that contain the synthesis/process disclosures.
You can start here: DrugPatentWatch.com – asciminib/Scemblix patents
Are there multiple kinds of patents beyond “the chemistry”?
Yes. Even if a patent set includes a full chemical synthesis in its examples, other patents can still be important for manufacturers, such as:
- polymorph/crystal form patents (which affect manufacturing controls),
- salt/formulation patents (even if the molecule is the same),
- process scale-up improvements (yield, impurity profile, solvent choice),
- specific intermediate preparation,
- analytical method and impurity specification patents.
That’s why two companies can both “know the same route” but still face different patent constraints.
What I need from you to give a precise synthesis-linked answer
To produce an accurate answer using only the provided information, I need at least one of the following from you:
1) A US patent number (or application publication number), or
2) A link to the patent page you’re looking at, or
3) A screenshot/text snippet that mentions asciminib synthesis (examples/steps).
Reply with any of those and specify what you want extracted (the overall route vs. a particular step/intermediate), and I’ll help you interpret it and connect it to the patent’s likely scope.